{"id":"W2947829857","doi":"10.1200/jco.2019.37.15_suppl.4012","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Nivolumab; Sorafenib; Gastroenterology; Hepatocellular carcinoma; Clinical endpoint; Randomized controlled trial; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009114163,0.0004756997,0.0008589796,0.0002176268,0.0001928866,0.0004565763,0.000349617,0.0004850841,0.003022459],"category_scores_gemma":[0.0006944418,0.0002116435,0.0009215341,0.0002966444,0.0002493827,0.0002808708,0.0002295636,0.001116754,0.0004919657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008189568,"about_ca_system_score_gemma":0.0006722042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001079784,"about_ca_topic_score_gemma":0.003691388,"domain_scores_codex":[0.9997883,0.0001044589,0.0000169105,0.00003230104,0.00002611603,0.00003191823],"domain_scores_gemma":[0.9996456,0.00008228052,0.00008659951,0.0000252828,0.00002316494,0.0001370633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6805929,0.01880919,0.01767079,0.001823473,0.00276686,0.0002629573,0.0001996411,0.003244289,0.02198917,0.0002237286,0.009584945,0.242832],"study_design_scores_gemma":[0.4962656,0.3965336,0.08325991,0.0002415766,0.00385524,0.0006028191,0.00007869314,0.002096013,0.004632778,0.0002538977,0.01212011,0.0000597054],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987671,0.006788454,0.0002879492,0.0004171068,0.00007458844,0.0008484058,0.0015221,0.00005072504,0.002339581],"genre_scores_gemma":[0.9903037,0.002952643,0.0007273534,0.0006752916,0.00008440251,0.0007615953,0.0026549,0.00001452023,0.001825614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003022459,"threshold_uncertainty_score":0.01011115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04717758825668757,"score_gpt":0.3612129806940574,"score_spread":0.3140353924373698,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}